Selected article for: "plasma concentration and serum concentration"
Author: Santiago, Llipsy; Uranga-Murillo, Iratxe; Arias, Maykel; González-Ramírez, Andrés Manuel; Macías-León, Javier; Moreo, Eduardo; Redrado, Sergio; García-García, Ana; Taleb, Víctor; Lira-Navarrete, Erandi; Hurtado-Guerrero, Ramón; Aguilo, Nacho; del Mar Encabo-Berzosa, Maria; Hidalgo, Sandra; Galvez, Eva M.; Ramirez-Labrada, Ariel; de Miguel, Diego; Benito, Rafael; Miranda, Patricia; Fernández, Antonio; Domingo, José María; Serrano, Laura; Yuste, Cristina; Villanueva-Saz, Sergio; Paño-Pardo, José Ramón; Pardo, Julián
Title: Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
  • Cord-id: 9kzo53a0
  • Document date: 2021_3_10
    • ID: 9kzo53a0
    Snippet: SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts wit
    Document: SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, with varying concentrations which correlate with previous disease severity and gender. Anti-RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against SARS-CoV-2 in vitro. ABSTRACT: Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • active infection and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • active infection and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active infection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active infection and addition clear: 1
    • active infection and lymphocyte population: 1
    • active infection patient and acute ards respiratory distress syndrome: 1
    • active infection patient and acute respiratory distress syndrome: 1, 2
    • active infection patient and acute respiratory syndrome: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and addition clear: 1
    • acute ards respiratory distress syndrome and additional factor: 1, 2
    • acute respiratory distress syndrome and addition clear: 1, 2
    • acute respiratory distress syndrome and additional factor: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and lymphocyte population: 1
    • acute respiratory syndrome and addition clear: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and additional factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and lod detection limit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and log dilution: 1, 2, 3, 4
    • acute respiratory syndrome and lozano blesa: 1
    • acute respiratory syndrome and lymphocyte population: 1, 2, 3